BioMarin Pharmaceuticals Inc vs Eli Lilly & Co.
BMRN vs LLY — side-by-side comparison from reported financials. BMRN leads 0, LLY leads 10 of 10 comparable metrics.
BioMarin Pharmaceuticals Inc
BMRN · Healthcare
$54.80-0.16%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | BMRN | LLY |
|---|---|---|
| Price | $54.80 | $1 177.20 |
| Market cap | $10.6B | $1.05T |
| Revenue (TTM) | $3.41B | $79.7B |
| Revenue growth | +15.4% | +31.7% |
| Net margin | 2.1% | 33.5% |
| Free cash flow | $738M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +1.8% | +37.6% |
| P/E | 145.4 | 41.6 |
| P/E vs own history (cheap-side %) | 45% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 1% | 93% |
| Altman Z-score | 1.70 | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 3,221 | 50,000 |
Full résumé-style profiles: BMRN CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.